Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGiME trial of prolonged darbepoetin alfa in low-risk myelodysplastic syndromes
ISRCTN98011567Phase 3Completed
- Sponsor
- Barts Health NHS Trust
- Start
- Nov 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of darbepoetin alfa and filgrastim in myelodysplastic syndrome (MDS) (3 arms), sponsored by Barts Health NHS Trust. Primary endpoints: Quality of life and Hemoglobin response. Started Nov 2010; status: completed.
02
Drugs
darbepoetin alfafilgrastim
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN98011567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN98011567.